Table 3.
Comparison of Changes in Biochemical Profiles and Clinical Factors in Patients With LC With or Without L‐Carnitine Supplementation
| Variables |
Overall (n = 70) |
L‐Carnitine Oral Administration Group (n = 35) |
L‐Carnitine Nonoral Administration Group (n = 35) |
P Value |
|---|---|---|---|---|
| White blood cell count, /μL | 0.00 (−3,400‐7,400) | −1,000 (−3,400‐2,100) | 1,000 (−1,900‐7,400) | 0.16 |
| NLR | 0.06 (−7.19‐7.24) | 0.06 (−7.19‐7.24) | 0.11 (−0.80‐5.26) | 0.47 |
| Hemoglobin, mg/dL | −0.40 (−4.70‐5.80) | 0.00 (−4.70‐5.80) | −0.70 (−4.10‐3.90) | 0.20 |
| Platelet counts, ×104/mm3 | 0.10 (−15.00‐7.80) | 0.20 (−4.90‐6.10) | 0.10 (−15.00‐7.80) | 0.44 |
| Prothrombin time, % | −1.45 (−35.3‐27.1) | −2.7 (−27.0‐39.0) | 0.70 (−35.3‐27.1) | 0.54 |
| Serum albumin, g/dL | 0.00 (−1.30‐1.40) | −0.05 (−1.30‐1.40) | 0.00 (−1.10‐1.00) | 0.94 |
| Total bilirubin, mg/dL | −0.1 (−3.8‐1.8) | −0.1 (−3.8‐1.8) | −0.1 (−0.5‐1.4) | 0.83 |
| Aspartate aminotransferase, IU/L | 1 (−55‐98) | 1 (−55‐93) | 1 (−27‐98) | 0.70 |
| Alanine aminotransferase, IU/L | 0 (−27‐55) | 0.50 (−27‐39) | −1.0 (−24‐55) | 0.49 |
| γ‐glutamyltransferase, IU/L | −1 (−222‐546) | −1 (−115‐546) | −1 (−222‐430) | 0.82 |
| Ammonia, mg/dL | −9 (−146‐146) | −31 (−146‐146) | 6 (−88‐115) | <0.01 |
| Cholinesterase, IU/L | −5.5 (−130‐68) | −2 (−66‐51) | −8 (−130‐68) | 0.78 |
| eGFR, mL/minute/1.73 m2 | −1.3 (−65.4‐33.1) | −2.3 (−65.4‐33.1) | −0.4 (−31.2‐23.0) | 0.35 |
| C reactive protein, mg/dL | 0.00 (−1.65‐4.05) | 0.00 (−1.65‐4.05) | 0.00 (−1.63‐1.07) | 0.15 |
| HbA1c, % | 0.0 (−2.1‐2.9) | 0.2 (−2.1‐1.7) | 0.0 (−2.1‐2.9) | 0.29 |
| Alpha‐fetoprotein, ng/mL | −0.25 (−1,434.1‐213,387.1) | −0.35 (−1,434.1‐37,454.6) | −0.05 (−11.0‐213,387.1) | 0.48 |
| FIB4‐index | 0.08 (−5.53‐16.18) | −0.11 (−5.53‐6.81) | 0.12 (−2.80‐16.18) | 0.56 |
Data are presented as number of patients or median (range) values.
Abbreviations: eGFR, estimated glomerular filtration ratio; FIB4, fibrosis‐4; HbA1c, hemoglobin A1c; NLR, neutrophil–lymphocyte ratio.